| 產(chǎn)品編號 | bs-12926R-Cy5 |
| 英文名稱 | Rabbit Anti-CYP1B1/Cy5 Conjugated antibody |
| 中文名稱 | Cy5標記的細胞色素cP4501B1抗體 |
| 別 名 | Aryl hydrocarbon hydroxylase; CP1B; CP1B1_HUMAN; Cyp1b1; CYPIB1; Cytochrome P450 1B1; cytochrome P450 family 1 subfamily B polypeptide 1; Cytochrome P450 subfamily I (dioxin inducible) polypeptide 1 (glaucoma 3 primary infantile); Flavoprotein linked monooxygenase; GLC3A; Microsomal monooxygenase; P4501B1; Xenobiotic monooxygenase. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 心血管 細胞生物 免疫學 信號轉(zhuǎn)導 新陳代謝 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Dog, Horse, ) |
| 產(chǎn)品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 61kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CYP1B1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Cytochrome P450 1B1 is a key enzyme involved in the production of potentially carcinogenic estrogen metabolites and the activation of environmental carcinogens and is the predominant member of the CYP1 family expressed in normal breast tissue and breast cancer. Estrogen has been proposed to trigger breast cancer development via an initiating mechanism involving its metabolite, catechol estrogen (CE). CYP1B1 catalyzes the conversion of 17-beta-estradiol to the catechol estrogen metabolites 2-OH-E2 and 4-OH-E2 which have both been postulated to be involved in mammary carcinogenesis. Genetic polymorphisms in CYP1B1 may play an important role in human prostate carcinogenesis as well. Polymorphism of the CYP1B1 gene at codon 432 (Val-->Leu) is associated with a change in catalytic function. Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Participates in the metabolism of an as-yet-unknown biologically active molecule that is a participant in eye development. Subcellular Location: Endoplasmic reticulum membrane. Microsome membrane. Tissue Specificity: Expressed in many tissues. DISEASE: Defects in CYP1B1 are the cause of primary congenital glaucoma type 3A (GLC3A) [MIM:231300]. GLC3A is an autosomal recessive form of primary congenital glaucoma (PCG). PCG is characterized by marked increase of intraocular pressure at birth or early childhood, large ocular globes (buphthalmos) and corneal edema. It results from developmental defects of the trabecular meshwork and anterior chamber angle of the eye that prevent adequate drainage of aqueous humor. Defects in CYP1B1 are a cause of primary open angle glaucoma (POAG) [MIM:137760]. POAG is a complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. The disease is asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes. Defects in CYP1B1 are a cause of Peters anomaly (PAN) [MIM:604229]. Peters anomaly is a congenital defect of the anterior chamber of the eye. Similarity: Belongs to the cytochrome P450 family. Database links: UniProtKB/Swiss-Prot: Q16678.2 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
